Humasis Co

Humasis Co Book Value Growth

The Book Value Growth of Humasis Co (205470.KQ) as of Nov 10, 2026 is -6.19 %. In the previous year, Book Value Growth was -20.21 % — a change of -69.35% (higher).

Book Value Growth

-6.19 %

YoY

-69.35%

Last updated:

Book Value Growth of Humasis Co is 2025 -6.19 % . Book Value Growth of Humasis Co was 2024 -20.21 % . It decreases by -69.35% higher compared to the previous year.

The Humasis Co Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2018
3.40 KRW
Jan 1, 2019
-5.47 KRW
Jan 1, 2020
220.39 KRW
Jan 1, 2021
313.60 KRW
Jan 1, 2022
71.65 KRW
Jan 1, 2023
-17.13 KRW
Jan 1, 2024
-20.21 KRW
Jan 1, 2025
-6.19 KRW
The Humasis Co Book Value Growth history
YEARBook Value GrowthYoY
-6.19 %-69.35%
-20.21 %+17.95%
-17.13 %-123.91%
71.65 %-77.15%
313.60 %+42.29%
220.39 %-4,130.50%
-5.47 %-260.84%
3.40 %-92.20%
43.58 %-189.22%
-48.85 %-3,836.42%
1.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Book Value Growth of Humasis Co is -6.19 % in 2025.

On Eulerpool you can find the complete historical development of Book Value Growth Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Humasis Co

All Key Metrics — Humasis Co